Literature DB >> 11996321

The in vivo metabolism of tibolone in animal species.

C H J Verhoeven1, R M E Vos, L P C Delbressine.   

Abstract

The in vivo tissue distribution and metabolism of tibolone was studied in different animals to further investigate the compound's tissue-specificity. Tibolone's metabolism was studied in vivo in rats and rabbits by administration of [16-3H]-tibolone and the metabolic pattern was determined in urine and faeces after oral administration to female rats and dogs. The main excretory pathway was found to be excretion in the faeces. Important phase-I metabolic routes were the reduction of the 3-keto to the 3a- or 3beta-hydroxy functions with a preference for 3alpha-OH in rats and for 3beta-OH in dogs. To a lesser extent, hydroxylation reactions at C2 and C7, and a shift of the delta5(10)-double bond to a delta4(5)-position also occurred. The main phase-II metabolic route was sulphate conjugation of the hydroxyl groups at C3 and C17. Since the oxidation reactions form only a minor part of the metabolism of tibolone, it is concluded that the cytochrome P450 enzymes do not play an important role in tibolone's metabolism. For both phases, quantitative differences were found between the species. In human similar metabolites are found. Profiling of the target organs in female rats and rabbits showed a tissue-specific distribution of metabolites. The majority of the metabolites existed as sulphate conjugates and no glucuronidated conjugates were observed. The same metabolites were found in both the circulation and the tissues. However, different tissues had quantitatively different metabolic profiles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996321     DOI: 10.1007/BF03190399

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

Review 1.  Livial: a review of clinical studies.

Authors:  R A Moore
Journal:  Br J Obstet Gynaecol       Date:  1999-03

2.  Species and strain differences in the epimerization of 3-beta, 17-beta-dihydroxy-17-alpha-ethynyl-delta-5 (10)-estrene to the 3 alpha-hydroxy epimer.

Authors:  R I Freudenthal; R Rosenfeld; M E Wall
Journal:  Biochem Pharmacol       Date:  1971-10       Impact factor: 5.858

3.  Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14).

Authors:  J de Visser; A Coert; H Feenstra; J van der Vies
Journal:  Arzneimittelforschung       Date:  1984

4.  Partial characterization of the cytosol 3 alpha-hydroxysteroid: NAD(P)+oxidoreductase of rat ventral prostate.

Authors:  J D Taurog; R J Moore; J D Wilson
Journal:  Biochemistry       Date:  1975-02-25       Impact factor: 3.162

5.  Molecular structure of rat hepatic 3 alpha-hydroxysteroid dehydrogenase. A member of the oxidoreductase gene family.

Authors:  A Stolz; M Rahimi-Kiani; D Ameis; E Chan; M Ronk; J E Shively
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

6.  Affinity labeling of human placental 3 beta-hydroxy-delta 5-steroid dehydrogenase and steroid delta-isomerase: evidence for bifunctional catalysis by a different conformation of the same protein for each enzyme activity.

Authors:  J L Thomas; R C Strickler; R P Myers; D F Covey
Journal:  Biochemistry       Date:  1992-06-23       Impact factor: 3.162

7.  Clinical profile of Org OD 14.

Authors:  L Tax; E M Goorissen; P M Kicovic
Journal:  Maturitas       Date:  1987       Impact factor: 4.342

8.  In vitro and in vivo metabolism of the progestagen Org 30659 in several species.

Authors:  C H Verhoeven; S F Krebbers; G N Wagenaars; C J Booy; G M Groothuis; P Olinga; R M Vos
Journal:  Drug Metab Dispos       Date:  1998-11       Impact factor: 3.922

9.  Indomethacin-sensitive 3 alpha-hydroxysteroid dehydrogenase in rat tissues.

Authors:  T E Smithgall; T M Penning
Journal:  Biochem Pharmacol       Date:  1985-03-15       Impact factor: 5.858

10.  Purification and properties of human hepatic 3 alpha-hydroxysteroid dehydrogenase.

Authors:  R B Iyer; J M Binstock; I S Schwartz; G G Gordon; B I Weinstein; A L Southren
Journal:  J Steroid Biochem Mol Biol       Date:  1992-10       Impact factor: 4.292

View more
  4 in total

1.  Pharmacokinetics of tibolone in early and late postmenopausal women.

Authors:  C J Timmer; H A M Verheul; D P Doorstam
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Application of UPLC-MS/MS for separation and quantification of 3α-Hydroxy Tibolone and comparative bioavailability of two Tibolone formulations in healthy volunteers.

Authors:  Vijay P Shinde; Ashutosh Pudage; Arvind Jangid; Hiren Mistri; P K Patel
Journal:  J Pharm Anal       Date:  2013-03-18

3.  Effect of tibolone pretreatment on kinases and phosphatases that regulate the expression and phosphorylation of Tau in the hippocampus of rats exposed to ozone.

Authors:  Rodolfo Pinto-Almazan; Julia J Segura-Uribe; Marvin A Soriano-Ursúa; Eunice D Farfán-García; Juan M Gallardo; Christian Guerra-Araiza
Journal:  Neural Regen Res       Date:  2018-03       Impact factor: 5.135

4.  Pharmacokinetics, tissue distribution and excretion of verticinone from F. hupehensis in rats.

Authors:  Xiao Wu; Jian-Guo Sun; Ying Peng; Yan Liang; Guang-Ji Wang; Hui Chen; Ji-Zhou Wu; Peng Zhang
Journal:  Molecules       Date:  2014-12-10       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.